Zepbound vs Wegovy: Cost, Coverage, and Which Weight-Loss Brand to Pick (2026)

If your only question is "which brand takes off more weight," Zepbound (tirzepatide) is the answer: it beat Wegovy (semaglutide) head-to-head in the only direct trial. Both sit among the most-used weight-loss options. But for most real shoppers the decision is settled at the pharmacy counter, not in a trial table, because both are FDA-approved and the live questions are price, coverage, and supply. This page is the brand-and-access decision: what each one costs in 2026, who insurance covers, vials versus pens, and what the ProtocolPlus community actually switches to.

Most "Zepbound vs Wegovy" pages either rehash the molecule science or quote a single list price and stop. We do two things differently. First, we lead with the part that actually moves the decision: the LillyDirect and NovoCare self-pay programs, savings cards, and coverage rules. Second, we add the signal no competitor has: among our users who tracked both, which brand they migrate to and why. The deep pharmacology lives on the molecule hubs, so this page stays a clean brand decision and links up for the science.

Key Takeaways

• Cheaper list price: Zepbound. Zepbound's cash list price runs about $1,086/month versus about $1,350/month for Wegovy (2026). But list price is rarely what people pay.
• Cheapest self-pay entry: Wegovy. Through NovoCare, Wegovy injections run about $199-$349/month (and the oral pill $149-$299), while Zepbound through LillyDirect runs about $299-$449/month for single-dose vials and pens. The brand that is cheaper flips depending on which program and dose you use.
• With commercial insurance both can hit ~$25/month via the manufacturer savings cards, but those cards do not work with Medicare or Medicaid.
• Coverage hinges on your diagnosis. Many plans cover the diabetes brands (Ozempic, Mounjaro) but decline the weight-loss brands (Wegovy, Zepbound) for obesity alone; a new Medicare GLP-1 Bridge (from Jul 2026) offers a $50/month copay for eligible enrollees.
• Most weight loss: Zepbound. It reduced weight about 20.2% vs Wegovy's 13.7% in the head-to-head SURMOUNT-5 trial. For the full science, see the molecule comparison linked below.
• What our community does: among ProtocolPlus users tracking these two for weight loss, the split is roughly 45% Wegovy, 55% Zepbound, and the net switch runs toward Zepbound about 2.5 to 1. A usage signal, not proof one is better for you.

Zepbound vs Wegovy at a glance

Here is the side-by-side before we go deep. Zepbound leads on raw weight loss and list price; Wegovy leads on the cheapest self-pay entry and on approvals beyond weight loss. Everything below this table explains the why, starting with cost because that is where the real decision lives.

The table is the headline. The two places the answer genuinely flips are cheapest self-pay entry (Wegovy, especially the oral pill) and maximum weight loss plus lower list price (Zepbound), so the real decision usually comes down to which of those you weight more, filtered by what your plan will actually cover.

What does Zepbound vs Wegovy actually cost in 2026?

The one-sentence answer: there is no single "price" for either brand, so the honest comparison is four prices each (list, self-pay program, savings card, and your insurance copay), and the cheaper brand flips depending on which one applies to you. List price is the number almost nobody pays; the self-pay programs and savings cards are what most cash and commercial-plan shoppers actually use.

Start with the sticker. As of 2026, Zepbound's cash list price is about $1,086 per month and Wegovy's is about $1,350 per month, so on list alone Zepbound is the cheaper brand by roughly $260 a month. But both makers run direct-to-consumer self-pay programs that cut that dramatically. Through LillyDirect, Zepbound single-dose vials and pens run about $299-$449 per month depending on dose (Lilly cut the lowest tiers in late 2025). Through NovoCare, Wegovy injections run about $199-$349 per month, and the newer oral Wegovy pill is even cheaper at about $149-$299. So when you compare the cash programs rather than list prices, Wegovy is usually the cheaper brand, the opposite of the list-price ranking.

The third price is the one most insured people land on. Both Novo Nordisk and Eli Lilly run manufacturer savings cards that, with a commercial (non-government) insurance plan that covers the drug, can bring the monthly copay down to as low as about $25. The catch is universal: those savings cards do not work with Medicare, Medicaid, or any federal plan. That single rule reshapes the whole decision for older and lower-income patients, which is the next section.

We deliberately do not pin a single "Zepbound is cheaper" or "Wegovy is cheaper" verdict, because it depends entirely on your path: list price favors Zepbound, the cash programs favor Wegovy, and with insurance they tie. Prices also moved repeatedly through late 2025 and 2026 (Novo has signaled a list-price cut for 2027), so treat every number here as a dated snapshot, not a quote.

Who does insurance actually cover, Zepbound or Wegovy?

The one-sentence answer: coverage depends far more on your diagnosis and plan type than on which brand is "better," and the savings cards that make either affordable are off-limits to anyone on a government plan. The single most useful thing to know is that obesity-only coverage is patchy, while a qualifying second diagnosis often unlocks a cheaper, better-covered path.

Here is the pattern that decides most cases. Many commercial plans will cover a GLP-1 for type 2 diabetes (which routes you to Ozempic or Mounjaro, the diabetes brands of the same molecules) but decline to cover the weight-loss brands, Wegovy and Zepbound, for obesity alone. When a plan does cover the weight-loss brand, prior authorization is the norm, and copays commonly land in the $25-$150 range depending on benefit design and deductible status. Wegovy's added approvals can help here: because it now carries cardiovascular-risk and MASH indications, some plans cover Wegovy for a patient with heart or liver disease who would not qualify on weight alone.

Government plans are the hard part. Medicare historically cannot cover a drug used purely for weight loss, and Medicaid coverage varies state by state. The notable 2026 change is the temporary Medicare GLP-1 Bridge (effective Jul 2026 through 2027), which offers eligible Part D enrollees a roughly $50/month copay on Wegovy and Zepbound; eligibility hinges on BMI thresholds. If you are on Medicare or Medicaid, that bridge, not the manufacturer savings card, is usually your route, because the savings cards explicitly exclude federal plans.

The practical takeaway: before you choose a brand on efficacy or price, check (1) whether your plan covers either weight-loss brand at all, (2) whether a second diagnosis routes you to a better-covered option, and (3) whether you are on a government plan that blocks the savings card. Those three answers often decide the brand before the trial data ever enters the conversation.

Vials, pens, and the supply story

The one-sentence answer: the form factor and availability now favor whatever the makers are pushing through their direct channels, and both have moved past the acute 2023-2024 shortages. The headline difference is that Zepbound is injection-only while Wegovy added an oral pill, and that Lilly leaned hard into cheaper single-dose vials.

On form, Wegovy is available as a weekly injector pen and, more recently, as an oral pill, which removes the needle entirely for people who dread self-injection. Zepbound is injection-only, available both as the KwikPen and as single-dose vials that you draw and inject yourself; those vials are the backbone of LillyDirect's cheaper self-pay tiers. The vial route is a bit more hands-on than a pen but is what makes Zepbound's $299-$449 cash pricing possible.

On supply, both molecules spent stretches of 2023-2024 on the FDA shortage list, which is what fueled the compounded-versions boom. As of 2026 the branded products are far more reliably available through the manufacturers' direct pharmacies, and the FDA has wound down the shortage designations that legally permitted large-scale compounding. That matters for the comparison because compounded "semaglutide" or "tirzepatide" is not the FDA-approved branded product, and the legal grey area around it has narrowed. If availability is your worry, the direct-from-maker channels (NovoCare, LillyDirect) are now the most dependable path for both brands.

What the ProtocolPlus community actually does between the two

This is the part no trial and no pharmacy page can give you: among users who have tracked both brands, which way do people move once they have lived with the cost, the side effects, and the monthly result? Trial data tells you what each brand can do in a study; it cannot tell you what real people decide afterward. The short version is that the traffic is mostly one-way toward Zepbound, but a meaningful minority go the other way for cost or tolerability, and a large group simply runs the strongest version they can get covered.

Three numbers carry the story, all from ProtocolPlus app data among the roughly 6,600 users tracking one of these two for weight loss:

• Adoption split: ~45% Wegovy, ~55% Zepbound. Zepbound is the larger camp, but it is not a blowout. Within the full ~11,400-user weight-loss cohort, Zepbound is 32% of all tracked options and Wegovy 26%.
• Co-tracking: ~16% (about 1,058 users) log both. These are people titrating across, comparing, or bridging supply or coverage gaps. Running both is common enough that "which one" is often really "which one first."
• Net switch favors Zepbound ~2.5 to 1. About 34% of Wegovy users (roughly 1,008) later moved to or added Zepbound, versus about 11% of Zepbound users (roughly 401) who moved the other way. The net flow, around 607 users, points to Zepbound.

Which way people switch (and why it is not unanimous)

The reverse flow is small but real, and it tells you who Wegovy is still right for: people whose plan covers it but not Zepbound, people who hit their goal without needing the extra push, and people for whom the cheaper self-pay or oral option matters month after month. Switching here is rarely a verdict that one brand is medically better. It is mostly people climbing toward the strongest tool they can access and afford, and being pulled back by whichever brand their wallet or insurer favors.

The timing of the typical switch is informative. The most common pattern is not "tried Wegovy briefly, bailed," but a switch after months on Wegovy, once weight loss flattens near the top dose. That plateau, not intolerance, is the usual trigger, and the destination is usually a mid-tier Zepbound dose rather than the maximum, because the added GIP pathway often restarts progress. The reverse moves cluster around two events: a coverage change that suddenly makes Zepbound unaffordable, and a switch to Wegovy's cheaper cash program. None of this is a protocol to run on your own, but it explains why the switch data leans the way it does.

The efficacy case, in brief (the science lives elsewhere)

The one-sentence answer: Zepbound produced clearly more weight loss than Wegovy in the only head-to-head trial, but this brand page keeps the science short on purpose and links you to the full molecule comparison. In SURMOUNT-5, the first direct trial (751 adults with obesity, no diabetes, 72 weeks), tirzepatide (Zepbound) reduced body weight about 20.2% versus about 13.7% for semaglutide (Wegovy), a difference near 6.5 percentage points. The gap widens at higher thresholds: nearly half of Zepbound patients lost 20% or more, versus about a quarter on Wegovy.

The mechanism behind the gap is that Wegovy's semaglutide acts on the GLP-1 receptor alone, while Zepbound's tirzepatide is a dual GIP and GLP-1 agonist, two appetite-and-metabolism pathways instead of one. That is the whole science in two sentences on purpose. We do not re-derive the trials here because the molecule-level head-to-head is owned by our dedicated comparison. For the full SURMOUNT-5 breakdown, the cross-trial caveats, mechanism, and dosing, read semaglutide vs tirzepatide, or the single-molecule guides for semaglutide and tirzepatide. To compare the diabetes-brand siblings, see Mounjaro vs Ozempic.

Tolerability: close enough that it rarely decides the brand

The one-sentence answer: both are GI-dominant and broadly similar to tolerate, so side effects rarely decide Zepbound versus Wegovy. In our community reports the most common effects line up almost on top of each other: nausea (Wegovy 44% vs Zepbound 42%), decreased appetite (40% vs 42%), diarrhea (30% vs 33%), constipation (24% vs 26%), and vomiting (22% vs 20%). These are self-reported community frequencies, not trial incidence and not proof of cause, but the pattern is clear: neither brand is the obviously gentler choice.

There is a subtle directionality experienced users describe: Wegovy complaints skew slightly toward nausea and constipation, Zepbound's a touch more toward diarrhea. The differences are small, but if you already know your gut it can tip the call. The far bigger lever for either brand is titration speed, since most severe GI episodes cluster around dose increases. Both share the same rare serious warnings, including a boxed warning for thyroid C-cell tumors based on rodent data, plus pancreatitis and gallbladder risks. For the complete tolerability breakdown, see semaglutide side effects and tirzepatide side effects; this page does not duplicate them.

The editorial scorecard (the "why," not the verdict)

The fit-score radar below rates each brand 1 to 5 on six dimensions. With equal weighting the two essentially tie (77 vs 77): Zepbound leads on effectiveness, Wegovy leads on cost (driven by its cheaper self-pay programs), and they match on evidence, safety, access, and speed. That tie is the honest summary. The community usage and the cost picture above, not this radar, are the headline signals, and your own priorities decide which dimension matters most.

Choose Wegovy if... / Choose Zepbound if...

The decision rarely needs a coin flip. These two cards cover the great majority of cases.

Choose Wegovy if:

• You want the cheapest self-pay entry. NovoCare lists Wegovy injections from about $199/month and the oral pill from about $149, the lowest cash starting points here.
• You want a needle-free option. Semaglutide exists as an oral pill; Zepbound is injection only.
• You have heart disease or liver disease (MASH): Wegovy carries the cardiovascular (2024) and MASH (2025) approvals, which can also unlock coverage.
• Your plan covers Wegovy (or Ozempic with a diabetes diagnosis) but not Zepbound.

Choose Zepbound if:

• Maximum weight loss is the priority. It beat Wegovy head-to-head in SURMOUNT-5 (about 20.2% vs 13.7%).
• You want the lower list price (about $1,086 vs $1,350/month) and can use LillyDirect single-dose vials from about $299/month.
• You also have obstructive sleep apnea with obesity: Zepbound is approved for it; Wegovy is not.
• You plateaued on Wegovy and want the added GIP pathway, the single most common move in our community data.

The honest verdict

If your only question is "which brand takes off more weight," Zepbound is the answer, and the community votes with its feet: the net switch runs about 2.5 to 1 toward it. But on the question that actually settles most decisions, money, there is no single winner: Zepbound is cheaper on list price, Wegovy is cheaper through its self-pay programs (and the oral pill), and with a commercial plan and savings card the two converge near $25. So the real verdict is conditional. If you are paying cash and want the lowest entry point, start with Wegovy's NovoCare pricing. If you have coverage or can absorb the cost and want the biggest result, Zepbound is the stronger brand. And before either, check what your insurer covers, because for many people coverage decides the brand before efficacy or price ever does.

To make it concrete, here is how the decision usually lands by situation:

• Most weight loss, cost not the deciding factor: Zepbound.
• Paying cash, want the lowest monthly entry: Wegovy (NovoCare from ~$199 injection, ~$149 oral).
• On a commercial plan that covers either, with a savings card: roughly a tie near $25/month; pick on efficacy or form.
• On Medicare or Medicaid: the savings cards do not apply; check the Medicare GLP-1 Bridge (~$50/month, from Jul 2026) and state Medicaid rules.
• Plateaued on Wegovy near the top dose: switch to Zepbound; this is the community's most common move.
• Heart disease or liver disease (MASH): Wegovy currently carries those added approvals.
• Obstructive sleep apnea with obesity: Zepbound is the one approved for it.
• Needles are a real barrier: Wegovy has an oral pill; Zepbound does not.

For the full molecule science behind these brands, see semaglutide vs tirzepatide and the semaglutide and tirzepatide guides. For the diabetes-brand siblings, see Mounjaro vs Ozempic. To see where both rank against every option people use, see best peptides for weight loss.

Frequently Asked Questions

Sources

• Aronne LJ, Horn DB, le Roux CW, et al. "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity" (SURMOUNT-5). New England Journal of Medicine, 2025. Retrieved 2026-06-18. https://www.nejm.org/doi/full/10.1056/NEJMoa2416394
• U.S. Food & Drug Administration. "FDA Approves New Medication for Chronic Weight Management" (Wegovy, semaglutide 2.4 mg). 2021. Retrieved 2026-06-18. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014
• U.S. Food & Drug Administration. "FDA Approves New Medication for Chronic Weight Management" (Zepbound, tirzepatide). 2023. Retrieved 2026-06-18. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
• U.S. Food & Drug Administration. "FDA Approves First Medication for Obstructive Sleep Apnea" (Zepbound). 2024. Retrieved 2026-06-18. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
• Eli Lilly. "Zepbound (tirzepatide) cost and self-pay pricing" (LillyDirect / pricinginfo.lilly.com). Retrieved 2026-06-18. https://pricinginfo.lilly.com/zepbound
• CNBC. "Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site." 2025. Retrieved 2026-06-18. https://www.cnbc.com/2025/12/01/eli-lilly-prices-zepbound-weight-loss-drug-vials.html
• Novo Nordisk / NovoCare. "Wegovy (semaglutide) self-pay pricing." Retrieved 2026-06-18. https://www.novocare.com/
• ProtocolPlus. "Community head-to-head data: Wegovy vs Zepbound" (head-to-head/semaglutide__tirzepatide.json). First-party app data, 2026. n ~ 6,612 users tracking one of the two for weight loss. Usage and switching signal, not a clinical efficacy verdict.